Abstract Purpose: Mortality from head and neck squamous cell carcinoma (HNSCC) is usually associated with locoregional invasion of the tumor into vital organs, including the airway. Understanding the signaling mechanisms that abrogate HNSCC invasion may reveal novel therapeutic targets for intervention. The purpose of this study was to investigate the efficacy of combined inhibition of c-Src and PLCg-1in the abrogation of HNSCC invasion. Experimental Design: PLCg-1 and c-Src inhibition was achieved by a combination of small molecule inhibitors and dominant negative approaches. The effect of inhibition of PLCg-1 and c-Src on invasion of HNSCC cells was assessed in an in vitro Matrigel-coated transwell invasion assay. In addition, the immunoprecipitation reactions and in silico database mining was used to examine the interactions between PLCg-1and c-Src. Results: Here, we show that inhibition of PLCg-1or c-Src with the PLC inhibitor U73122 or the Src family inhibitor AZD0530 or using dominant-negative constructs attenuated epidermal growth factor (EGF)^stimulated HNSCC invasion. Furthermore, EGF stimulation increased the association between PLCg-1 and c-Src in HNSCC cells. Combined inhibition of PLCg-1 and c-Src resulted in further attenuation of HNSCC cell invasion in vitro. Conclusions: These cumulative results suggest that PLCg-1 and c-Src activation contribute to HNSCC invasion downstream of EGF receptor and that targeting these pathways may be a novel strategy to prevent tumor invasion in HNSCC.
Head and neck squamous cell carcinoma (HNSCC) continues to be the sixth most common cancer in the world and a major cause of cancer morbidity and mortality. The treatment of HNSCC has primarily relied on standard approaches, including surgery, radiation, and chemotherapy or a combination of these methods, with little improvement in outcome. Most HNSCC tumors rapidly invade the normal surrounding stroma and metastasize to regional lymph nodes. Understanding the molecular mechanisms responsible for the highly invasive nature of HNSCC tumors is vital to develop more effective strategies to manage this disease.
Epidermal growth factor (EGF) receptor (EGFR) is essential not only for cell survival but also plays an important role in cell motility and invasion. Several signaling pathways leading to altered cellular phenotypes are triggered downstream of EGFR in HNSCC cells. We previously showed that EGFR activates PLCg-1, resulting in an increase in HNSCC cell invasion (1) . Others have reported that PLCg-1 inhibition decreases the invasion of prostate and breast carcinoma cells (2) . Thus PLCg-1 plays a crucial role in invasion of HNSCC and other tumor types. In addition to PLCg-1, c-Src has also been implicated in cancer invasion (3 -5) . A nonreceptor tyrosine kinase, c-Src, is a proto-oncogene that is overexpressed in several cancers including HNSCC, breast, prostate, and colon carcinoma (6 -9) . We have previously reported that c-Src directly associates with EGFR in HNSCC cells upon EGF stimulation (10) .
The cooperative role of PLCg-1 and c-Src in mediating tumor cell invasion downstream of EGFR has not been previously investigated. The present study was undertaken to test the hypothesis that PLCg-1 and c-Src interact with each other upon EGF stimulation, and activation of these proteins contribute to promoting HNSCC tumor cell invasion. We examined PLCg-1 expression levels in HNSCC cells derived from primary and metastatic HNSCC tumors. Inhibition of PLCg-1 or c-Src activation, using either pharmacologic inhibitors or dominant-negative mutants, abrogated EGF-stimulated HNSCC cell invasion. Additional investigation showed that EGF stimulation increased the association between PLCg-1 and c-Src in HNSCC cells and that combined inhibition of PLCg-1 and c-Src resulted in further abrogation of HNSCC cell invasion. These cumulative results suggest that PLCg-1 and c-Src interact with each other on EGF stimulation and that activation of PLCg-1 and c-Src via EGFR contributes to HNSCC invasion. These results suggest that combined inhibition of PLCg-1 and c-Src represents a potential strategy to prevent tumor invasion and metastasis in HNSCC.
Materials and Methods
Cell lines. HNSCC cell lines PCI-15A, PCI-37A, and UM-22A were derived from primary HNSCC tumor tissue, and PCI-15B, PCI-37B, and UM-22B were derived from matched metastatic lymph nodes, respectively, as described previously (11) . Cells were maintained in DMEM with 10% heat-inactivated fetal bovine serum (FBS; Life Technologies, Inc.) at 37jC with 5% CO 2 . Previously described human HNSCC cell line OSC-19, derived from a metastatic lymph node, was cultured in improved Eagle's MEM containing 10% heat-inactivated FBS and nonessential amino acids (0.1 mmol/L; ref. 11).
Reagents. For in vitro cell stimulation, recombinant human EGF (Sigma Chemical Co.) was used. U73122 (BioMol) was used to block PLC activity. An inactive analogue of U73122, U73343 (BioMol), was used as a negative control. Antibodies used included mouse monoclonal anti -PLCg-1 (Upstate Biotechnology), anti -phosphorylated PLCg-1 (Cell Signaling Technologies), anti -phosphorylated focal adhesion kinase (FAK; Cell Signaling Technologies), tubulin (Abcam, Inc.), and h-actin (Calbiochem-Novabiochem Corporation). Antibodies against the activation loop of Src (PY418) and total c-Src were purchased from Biosource International and Santa Cruz Biotechnology, respectively. The c-Src inhibitor AZD0530 was supplied by AstraZeneca Pharmaceuticals.
Transfection of HNSCC cells with dominant-negative PLCg-1. Previously described HNSCC cell line PCI-37A engineered to express dominant-negative Src (K296R/528F) cDNA was used in these studies (12) . An expression vector coding for a dominant-negative PLCg-1 fragment (PLCz), as previously described, was stably transfected into a representative HNSCC cell line ref. 13) . Colonies obtained after selection were characterized by immunoblotting for levels of activated PLCg-1 with or without EGF stimulation. Clones where EGF stimulation failed to activate PLCg-1 were used in this study.
Immunoblotting. HNSCC cells were plated at 4 Â 10 5 cells per 100-mm dish. Twenty-four hours after plating, cells were serum starved for 72 h. During serum starvation the media was changed every 24 hours. For the experiments with inhibitors, cells were treated with 3 Amol/L of either U73122 or U73343 for 25 min or 1 Amol/L AZD0530 for 4 h followed by stimulation with 10 ng/mL of recombinant human EGF or 10% FBS for 5 min. After EGFR stimulation, cells were washed thrice with cold PBS and lysed as previously described (14) . Forty-microgram protein was size-fractionated through an 8% SDS-PAGE gel and immunoblotted for phosphorylated and total PLCg-1, c-Src, FAK, h-actin.
Immunoprecipitation. For immunoprecipitation, 200 Ag of protein was precipitated with anti -c-Src antibody (Cell Signaling Technologies) or anti -PLCg-1 (Upstate Biotechnology) or antimouse IgG as a control and protein agarose G beads (Invitrogen). The immunoprecipitated proteins then were resolved on an 8% SDS-PAGE gel and immunoblotted for anti -pPLCg-1 antibody (Cell Signaling Technologies) or PY418 antibody. To show equal loading of protein among various lanes, immunoblots were stripped in Restore Western Blot Stripping Buffer (Pierce), blocked, and probed with anti -PLCg-1 antibody (Cell Signaling Technologies) or anti -c-Src antibody (Santa Cruz Biotechnology).
In vitro invasion of HNSCC cells. Cell invasiveness was evaluated in vitro using Matrigel-coated semipermeable-modified Boyden inserts with a pore size of 8 Am (Becton Dickinson/Biocoat). HNSCC cells (2.5 Â 10 4 ) were plated in serum-free medium in the insert. The lower chamber contained DMEM + 10% FBS that served as a chemoattractant. Cells were treated in the presence or absence of EGF (10 ng/mL) and/or U73122 (3 Amol/L), U73343 (3 Amol/L), or AZD0530 (1 Amol/L). To control for effect of inhibitors or growth factors on cell growth, the cells were also plated in parallel in a 96-well plate under identical conditions. After 48 h of treatment at 37jC in a 5% CO 2 incubator, the cells in the insert were removed by wiping gently with a cotton swab. Cells on the reverse side of the insert were fixed and stained using Hema 3 (Fisher Scientifics) according to the manufacturer's instructions. Invading cells in four representative fields were counted using light microscopy at 200Â magnification. Mean F SE was calculated from three independent experiments. Cells plated on the 96-well plate were assessed via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay for metabolically active cells. Under the conditions used in the assay, there was no significant difference in the cell number between various treatment conditions.
Database mining to examine interactions between EGFR, PLCg-1, and c-Src. The Human Protein Reference database 8 was used to identify publications documenting physical pair-wise interaction between PLCg-1, EGFR, and c-Src. In addition, a total of 27 features from eight different data sources were collected to identify indirect evidences, further supporting their interactions. Three types of ''similarity'' features were derived from the Gene Ontology database (15) , subcellular colocalization, functional categorization, and pathway membership. Domain-domain interactions were derived based on the hypergeometric distribution (16) . Finally, we compared if there are homologous proteins in yeast and the known yeast protein-protein interactions derived from the corresponding interactions between the human proteins (17) .
In addition to qualitatively comparing the entries in the databases for the three proteins, we also investigated the similarities quantitatively, using a classification framework (18) . Each of the indirect data provides partial information about interacting pairs and, together, contributes to the likelihood that two proteins interact. We developed a classification strategy to integrate the evidences from different data sources (18) . By transforming the multiple data sources into a feature vector for every pair of proteins, we learned from HPRD-derived training data those features that distinguish interacting from noninteracting proteins. In a binary classification computational framework, we applied the Random Forest method to differentiate the two classes of proteins (17) . Based on the score assigned to an interaction by the Random Forest, we estimated the confidence in an interaction based on the multiple evidences.
Statistical analysis. Statistical analysis was done using the exact Wilcoxon test to determine the statistical significance of the differences between groups using STATXact Version 6.0 (Cytel, Inc.).
Results
PLCg-1 expression levels are elevated in the metastatic tumorderived HNSCC cell lines. We previously reported that PLCg-1 mediates cellular migration and invasion downstream of EGFR where increased expression of PLCg-1 was observed in HNSCC tumors compared with levels in normal adjacent mucosa (1) . To determine the role of PLCg-1 in tumor progression from primary tumor to metastatic tumor, four HNSCC cell lines derived from the primary tumor and the paired metastatic lymph node from the same patient were analyzed via immunoblotting for total and phosphorylated PLCg-1 levels. The primary and metastatic HNSCC cell lines were analyzed by immunoblotting for PLCg-1. In all three paired cell lines, a 1.4-fold to 2.4-fold increase in PLCg-1 expression levels were detected in the metastatic tumor -derived HNSCC cell line compared with paired primary tumor -derived cell line (Fig. 1) .
HNSCC cell lines derived from metastatic lymph nodes are more invasive than those derived from primary tumors. Molecular alterations in the primary tumor contribute to the metastatic spread of HNSCC tumors (19) . Previous reports have shown that up-regulation of molecules involved in motility, including integrins, are associated with HNSCC invasion (20) . Because expression and activation of PLC g-1 was increased in cells derived from metastatic lymph nodes, we examined the invasive capacity of the paired primary and metastatic lymph node -derived HNSCC cells in vitro. Matrigel invasion assays were done in three paired HNSCC cell lines over 48 h. HNSCC cells derived from the primary tumor were less invasive than cells derived from the lymph node metastasis, suggesting that increased PLCg-1 expression may correlate with an increase in the invasive capacity of HNSCC cells (Fig. 2) .
Inhibition of PLCg-1 partially abrogates HNSCC cell invasion in vitro. PLCg-1 is phosphorylated by EGFR on ligand stimulation (1) . Further phosphorylation of PLCg-1 results in an increase in inositol phosphate turnover, indicating increased PLCg-1 activity (1). Thus, phosphorylation of PLCg-1 results in activation of the enzyme triggering downstream effects, including increase in inositol phosphate and diacyl glycerol levels. To examine the effect of decreased PLCg-1 on HNSCC invasion in vitro, HNSCC cells were transfected with dominantnegative PLCg-1 or with the empty vector. Transfected clones were characterized by testing for PLCg-1 activation in the presence of EGF stimulation. EGFR stimulation increased activation of PLCg-1 in vector control -transfected HNSCC cells, but not in dominant-negative PLCg-1 expressing cells (Fig. 3A) . HNSCC cells expressing dominant-negative PLCg-1 were next examined for invasion in vitro in response to EGF or serum stimulation. Cells expressing dominant-negative PLCg-1 did invade in response to EGF and serum stimulation but to a lesser extent when compared with the vector control cells (Fig.  3B) . Thus, although PLCg-1 plays a role in EGFR-mediated HNSCC cell invasion, other molecules downstream of EGFR may also contribute to HNSCC invasion.
Inhibition of c-Src activation on EGFR stimulation abrogates HNSCC cell invasion in vitro. We have previously shown that c-Src may be involved in EGFR-mediated invasion in HNSCC (12) . To examine the efficacy of combined inhibition of both PLCg-1 and c-Src in abrogating HNSCC invasion, we first determined strategies to inhibit EGFR-mediated c-Src activation in HNSCC cells. We have previously shown that c-Src directly associates with EGFR upon EGF stimulation in HNSCC cells (12) . To determine the effect of c-Src inhibition on EGFRmediated invasion, we tested the efficacy of a small molecule inhibitor and a dominant-negative c-Src approach. Cells were pretreated for 4 h with the Src inhibitor AZD0530 and were then stimulated with recombinant EGF (10 ng/mL) or 10% FBS containing medium for 5 min. Protein extracts were fractionated on an SDS-PAGE gel. Immunoblotting was done with anti -phosphorylated c-Src antibody (PY418) followed by anti -c-Src antibody to show equal loading. HNSCC cells treated with the Src inhibitor AZD0530 did not activate c-Src on EGFR stimulation compared with the vehicle control -treated cells (Fig. 4A ). This indicates that AZD0530 effectively inhibits tyrosine kinase receptor -mediated c-Src activation in HNSCC cells. Recently, c-Src was reported to mediate its invasive effects in breast cancer cells through activation of FAK (21) . To determine if the increase in phosphorylated c-Src on EGF stimulation correlates with any meaningful change in c-Src kinase activity, we examined the effect of c-Src inhibition on activation of FAK. Our data show that in 37A cells EGF stimulation results in increase in phosphorylation of FAK (Fig. 4B) . Pretreatment of the cells with Src inhibitor AZD0530 resulted in a reduction in EGF-mediated phosphorylation of FAK. However, in addition to c-Src, AZD0530 also inhibits (Fig. 6A and B) . IgG control lanes showed that there was no nonspecific binding on the antibody to c-Src or PLCg-1.
Database mining results. The human protein reference database lists publications documenting physical pair-wise interactions (24 -27) . All three proteins PLCg-1, EGFR, and c-Src are known to interact with each other physically. In addition to the direct evidence for physical interaction, we also investigated other biological databases that could provide indirect evidence corroborating the physical and functional linkage between these proteins. Each of these indirect data provides partial information about interacting pairs, and all features together contribute to the likelihood that two proteins interact. We analyzed the features both qualitatively and using a computational framework, in which interacting proteins are distinguished from noninteracting proteins by solving a binary classification task (18) . We found that the scores for all three sets of interactions are very high, typical of interactions of high confidence. The highest score was found in the case of the EGFR/c-Src interaction, second highest in the case of the PLCg-1/c-Src, and third highest in the case of the EGFR/PLCg-1 interaction. In terms of individual features, gene ontology functional similarity was found for the PLCg-1/c-Src pair, which share signal transducer and protein binding categories, and the EGFR/c-Src pair, which share protein kinase and transferase activities.
Discussion
Due to the close proximity of vital structures in the head and neck region, tumor invasion increases morbidity and mortality in HNSCC patients. Therapies that prevent HNSCC tumor invasion and metastasis may facilitate the management of this disease by containing of the tumor at the site of origin. Aberrant expression and signaling of several proteins has been implicated in tumor progression to metastatic phenotypes. Upregulation of EGFR has been associated with increased We previously reported that PLCg-1 levels are higher in HNSCC tumor tissue compared with normal adjacent mucosa and PLCg-1 blockade reduces EGFR ligand -mediated cell invasion in vitro (1) . In the present study, we showed that PLCg-1 expression and activation levels are elevated in the metastatic tumor -derived HNSCC cell lines compared with levels in paired primary tumor -derived cell lines. PLCg-1 is activated by receptor tyrosine kinases by recruitment of the lipase to the autophosphorylated receptor and subsequent tyrosine phosphorylation (28 -30) . Activation of PLCg-1 results in the production of the second messengers, such as diacylglycerol and inositol 1,4,5-trisphosphate and subsequent activation of protein kinase C isoforms, plays an important role in diverse cellular responses, including cytoskeletal rearrangement (31, 32) . Inositol 1,4,5-trisphosphate binding to intracellular receptors induces an increase in cytosolic calcium levels and elevated intracellular calcium levels in tumor cells are associated with increased cell motility (33) . Thus, elevated PLCg-1 expression and activation may cause increased cell motility in HNSCC cells. Our results, comparing the invasiveness between metastatic and primary tumor-derived HNSCC cells, suggest that elevated PLCg-1 expression and activation may correlate with cell invasion and that PLCg-1 activity is required for EGFR-mediated cell motility in HNSCC. Furthermore, we also showed that inhibition of PLCg-1 abrogates EGFR-mediated HNSCC cell invasion in PLC inhibitor -treated and dominant-negative PLCg-1 expressing HNSCC cells. These In addition to PLCg-1, it has been reported that c-Src expression and activation are elevated in a various of human tumors, including breast, colon, prostate, and head and neck (6, 9, 34, 35) . Increased Src activity has been reported to correlate with the loss of epithelial differentiation and acquisition of a fibroblastic-like phenotype, which is involved in the metastatic potential of carcinoma cells (4) . We previously showed that c-Src directly associates with EGFR upon EGF stimulation and c-Src activation contributes to HNSCC cell invasion (12) . Although c-Src expression levels were not elevated in the metastatic tumor -derived HNSCC cell lines compared with levels in paired primary tumor -derived cell lines (data not shown), inhibition of c-Src activation on EGFR stimulation by pharmacologic (AZD0530) and dominantnegative methods abrogates HNSCC cell invasion. AZD0530 is a highly selective inhibitor of nonreceptor tyrosine kinases, including c-Src, c-Yes, Lck, and Abl (22) . We show that AZD0530 inhibited c-Src activation mediated by EGFR stimulation in HNSCC cells and significantly suppressed the invasive nature of HNSCC cells in vitro. The reduced invasion of HNSCC cells, as a result of c-Src inhibition by AZD0530, emphasizes the important role of c-Src signaling in HNSCC cell invasion. Others have reported that AZD0530 is a potent inhibitor of cell migration, and combined treatment with EGFR inhibitor showed markedly additive effects toward inhibition of cell motility and invasion in breast carcinoma cells (36) . Recently, it has been shown that an EGFR tyrosine kinase inhibitor suppresses c-Src and p21-activated kinase 1 activation and invasiveness of HNSCC and breast cancer cells on EGF stimulation (37) . Taken together, these data indicate that cSrc activation mediated by EGFR likely contributes to the invasiveness and metastatic potential of HNSCC cells.
Because inhibition of PLCg-1 or c-Src abrogates EGFstimulated HNSCC cell invasion in vitro, we hypothesized that combined inhibition of both PLCg-1 and c-Src would further abrogate HNSCC cell invasion. In the present study, we showed that HNSCC cell invasion upon EGF stimulation was almost completely blocked by combined inhibition of both PLCg-1 and c-Src by pharmacologic and dominantnegative methods. To our knowledge, this is the first report to show the combined inhibition of both PLCg-1 and c-Src abrogates EGFR-mediated tumor cell invasion. Further testing in in vivo preclinical models will be required to fully explore the translational significance of this strategy. To elucidate the mechanism of the combined effect, we examined the interaction of these molecules in HNSCC cells stimulated with EGF. Our results indicate that the interaction between PLCg-1 and c-Src was significantly increased in HNSCC cells stimulated with EGF and that this effect could be blocked in dominant-negative PLCg-1 or c-Src -transfected HNSCC cells. c-Src contains SH2 and SH3 domains which mediate intramolecular protein-protein interactions (38, 39) and interacts functionally and physically with the transmembrane tyrosine kinase receptors for several growth factors, including EGF (24, 26, 40, 41) . The SH2 domain interactions with activated EGFR results in the phosphorylation of c-Src inducing mitogenesis and cell invasion in several cancers (37, 42) . Phosphorylated EGFR has been shown to form heteromeric complexes with multiple signaling and bridging molecules via SH2-phosphotyrosine interactions (43, 44) . The SH2 domain of c-Src has been shown to directly interact with activated EGFR in vitro (26) . In contrast, others have reported that c-Src interacts with EGFR indirectly through intermediary proteins, such as the mucin-like transmembrane glycoprotein via subsequent SH2-dependent binding of c-Src (45) . Similarly, the SH2 domains of PLCg-1 also mediate the association with a receptor tyrosine kinase, such as EGFR (46, 47) . The SH2 domains of PLCg-1 bind to phosphotyrosinecontaining peptides and mediate the recruitment of SH2 domain -containing target proteins to activated EGFR. PLCg-1 can interact with the activated EGFR by a mechanism that involves the N-SH2 domain as a primary association event and the C-SH2 domain as a secondary event necessary for a maximal level of association (48) . Furthermore, PLCg-1 can associate with several signaling molecules, including kinases of the Src family (49, 50) .
The binding of EGF to its receptor induces dimerization of receptor subunits and stimulation of the tyrosine kinase activity of EGFR and results in autophosphorylation of EGFR on specific tyrosine residues. These phosphorylated tyrosine residues in EGFR initiate cellular signaling by acting as highaffinity binding sites for the SH2 domains of various effector proteins, such as PLCg-1 and c-Src. PLCg-1 and c-Src bind directly or indirectly to phosphorylated tyrosine residues on EGFR. The close proximity of PLCg-1 and c-Src in the receptor complex may promote reciprocal SH2 domain interactions (26, 45 -47, 51, 52) . Further exploration of in silico databases revealed that PLCg-1 and c-Src can directly interact with each other and also share numerous indirect features that make them likely to interact with each other, corroborating our findings in HNSCC cells. We previously showed that EGFR and PLCg-1 are overexpressed in HNSCC (1, 53) . Overexpression of SH2 domain -containing proteins may lead to signal amplification through enhanced recruitment of the enzyme to activated receptors, suggesting that the resulting synergistic signaling will occur to a much greater extent in HNSCC cells and may increase EGFR-mediated HNSCC cell invasion.
In conclusion, we report here that EGFR activation increases the interaction of both PLCg-1 and c-Src in HNSCC cells and combined inhibition of these molecules can block EGFRmediated HNSCC cell invasion.
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